Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir
about
Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
P2860
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@ast
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@en
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@nl
type
label
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@ast
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@en
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@nl
prefLabel
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@ast
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@en
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@nl
P2093
P2860
P356
P1476
Dose separation does not overc ...... enavir and lopinavir/ritonavir
@en
P2093
Amanda H Corbett
Angela D M Kashuba
Hsiao-Chuan Tien
Kristine B Patterson
Leslie A Kalvass
Linh T Ngo
Michael L Lim
P2860
P304
P356
10.1128/AAC.01006-05
P407
P577
2006-08-01T00:00:00Z